<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722020</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0078</org_study_id>
    <nct_id>NCT00722020</nct_id>
  </id_info>
  <brief_title>HFCWO in Hospitalized Asthmatic Children</brief_title>
  <official_title>High Frequency Chest Wall Oscillation in Hospital Management of Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hill-Rom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hill-Rom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether or not high frequency chest wall oscillation (in the form of the VestTM)
      is superior to regular asthma therapy in the management of children hospitalized with
      moderate to severe asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A historically controlled pilot study was conducted in pediatric patients 18 months to 18
      years of age hospitalized with a diagnosis of asthma or reactive airway disease and admitted
      to the pediatric intensive care unit. Upon receiving informed consent, patients were treated
      with HFCWO therapy via the VEST. The primary endpoint was time to readiness for discharge,
      lack of need for continued supportive care (e.g., intravenous fluid or oxygen), and
      bronchodilator treatments spaced at least four hours apart.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint Will be Time to Readiness for Discharge.</measure>
    <time_frame>30 days</time_frame>
    <description>Days in the hospital prior to patient being clinically ready to discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint Total Hospital Length of Stay</measure>
    <time_frame>30 Days</time_frame>
    <description>Seconadary endpoint was Total Hospital length of stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Bronchial Asthma</condition>
  <condition>Asthma</condition>
  <condition>Status Asthmaticus</condition>
  <arm_group>
    <arm_group_label>Vest Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical control for PICU asthma patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VEST</intervention_name>
    <description>15 minutes of HFCWO via the Vest 2-3 times daily</description>
    <arm_group_label>Vest Arm</arm_group_label>
    <other_name>Hill-Rom Vest(tm)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any pediatric patient between the ages of 18 months and 18 years admitted to Winthrop
             University Hospital's pediatric floor or intensive care unit with a diagnosis of
             asthma or reactive airway disease

        Exclusion Criteria:

          -  Patients with chronic, comorbid respiratory conditions (e.g., cerebral palsy, cystic
             fibrosis)

          -  Those who regularly use HFCWO

          -  Any patient exhibiting an absolute contraindication to HFCWO therapy

          -  Absolute contraindications to using HFCWO include head and neck injury prior to
             stabilization, and active hemorrhage with hemodynamic instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthrop University Hospital, Winthrop Pediatric Associates</name>
      <address>
        <city>Long Island City</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Long Island City</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <results_first_submitted>August 25, 2015</results_first_submitted>
  <results_first_submitted_qc>October 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2015</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Bronchial Disease</keyword>
  <keyword>Status Asthmaticus</keyword>
  <keyword>High Frequency Chest Wall Oscillation</keyword>
  <keyword>the Vest</keyword>
  <keyword>HFCWO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HFCWO / VEST Group</title>
          <description>Patients will receive HFCWO therapy via the VEST(TM). Each Vest treatment will be accompanied by a simultaneous nebulized bronchodilator treatment.
High Frequency Chest Wall Oscillation via Vest (Hill-Rom Vest(tm)): Simultaneous to bronchodilator treatment via nebulizer (regular treatment), patients will receive 15 minutes of HFCWO via the Vest.</description>
        </group>
        <group group_id="P2">
          <title>Standard Care</title>
          <description>Regular nebulized bronchodilator treatment. Sham Vest treatment as investigator is blinded to whether patient actually received Vest treatment.
Regular nebulized bronchodilator treatment.: Sham Vest treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pediatric patients admitted with diagnosis of Asthma</population>
      <group_list>
        <group group_id="B1">
          <title>HFCWO / VEST</title>
          <description>Pediatric patients with primary diagnosis of Asthma received HFCWO therapy via the VEST(TM). Each Vest treatment will be accompanied by a simultaneous nebulized bronchodilator treatment. Patients receive 15 minutes of HFCWO via the Vest.</description>
        </group>
        <group group_id="B2">
          <title>Standard Care With Sham Vest</title>
          <description>Regular nebulized bronchodilator treatment. Sham Vest treatment as investigator is blinded to whether patient actually received Vest treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="2.3"/>
                    <measurement group_id="B2" value="8.2" spread="2.0"/>
                    <measurement group_id="B3" value="8.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint Will be Time to Readiness for Discharge.</title>
        <description>Days in the hospital prior to patient being clinically ready to discharge</description>
        <time_frame>30 days</time_frame>
        <population>asthmatic children</population>
        <group_list>
          <group group_id="O1">
            <title>HFCWO / VEST Group</title>
            <description>Patients will receive HFCWO therapy via the VEST(TM). Each Vest treatment will be accompanied by a simultaneous nebulized bronchodilator treatment.
High Frequency Chest Wall Oscillation via Vest (Hill-Rom Vest(tm)): Simultaneous to bronchodilator treatment via nebulizer (regular treatment), patients will receive 15 minutes of HFCWO via the Vest.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Regular nebulized bronchodilator treatment. Sham Vest treatment as investigator is blinded to whether patient actually received Vest treatment.
Regular nebulized bronchodilator treatment.: Sham Vest treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint Will be Time to Readiness for Discharge.</title>
          <description>Days in the hospital prior to patient being clinically ready to discharge</description>
          <population>asthmatic children</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread=".7"/>
                    <measurement group_id="O2" value="1.75" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Endpoint Total Hospital Length of Stay</title>
        <description>Seconadary endpoint was Total Hospital length of stay</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HFCWO / VEST</title>
            <description>Pediatric patients with primary diagnosis of Asthma received HFCWO therapy via the VEST(TM). Each Vest treatment will be accompanied by a simultaneous nebulized bronchodilator treatment. Patients receive 15 minutes of HFCWO via the Vest.</description>
          </group>
          <group group_id="O2">
            <title>Standard Care With Sham Vest</title>
            <description>Regular nebulized bronchodilator treatment. Sham Vest treatment as investigator is blinded to whether patient actually received Vest treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Endpoint Total Hospital Length of Stay</title>
          <description>Seconadary endpoint was Total Hospital length of stay</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>ICU admission and hospital admission time</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HFCWO / VEST</title>
          <description>Pediatric patients with primary diagnosis of Asthma received HFCWO therapy via the VEST(TM). Each Vest treatment will be accompanied by a simultaneous nebulized bronchodilator treatment. Patients receive 15 minutes of HFCWO via the Vest.</description>
        </group>
        <group group_id="E2">
          <title>Standard Care With Sham Vest</title>
          <description>Regular nebulized bronchodilator treatment. Sham Vest treatment as investigator is blinded to whether patient actually received Vest treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon Roberts, MD</name_or_title>
      <organization>Winthrop University</organization>
      <phone>516-663-4600</phone>
      <email>jroberts@winthrop.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

